FDA currently approves Comirnaty and Pfizer-BioNTech Covid-19 Vaccine for active immunization to prevent coronavirus disease (COVID-19) in individuals 16 years of age and older. It is also approved under emergency use authorization as a two-dose primary series for individuals 5 years of age and older, as a third primary series dose for individuals 5 years of age and older who have been determined to have certain kinds of immunocompromise, and as a single booster dose for individuals 12 years of age and older at least five months after completing a primary series of the vaccine.
Contraindications to Comirnaty and Pfizer-BioNTech Covid-19 Vaccine includes Allergy or Hypersensitivity
Warnings and Precautions
• Increased risk of myocarditis or pericarditis
• Syncopy following administration